Economic burden of asthma: Implications for outcomes and cost-effectiveness analyses

Daniel C. Malone, Edward P. Armstrong

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Asthma is a disease of chronic airway inflammation. It is of importance to clinicians and health systems because the hospitalization and death rate due to asthma have increased since 1980. Cost of illness studies have estimated that the total cost of asthma (direct and indirect costs) exceed $10 billion annually, in the USA. Since 1985, the proportion of asthma costs in hospitals have decreased and the proportion of costs due to asthma medications have increased. However, approximately half of direct medical costs of asthma are due to hospitalizations. The mean direct cost of asthma per year per patient has been estimated to be approximately $1100. As the implementation of national and international guidelines continues, future costs for asthma will likely come from the treatment and management of the disease. Adequate assessments of treatment and cost-effectiveness analysis are important. Recommendations promoting the use of cost-effective anti-inflammatory medications are crucial to efficiently managing asthma.

Original languageEnglish (US)
Pages (from-to)177-186
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number2
StatePublished - 2001


  • Asthma
  • Corticosteroids
  • Cost
  • Cost of illness
  • Cost-effectiveness
  • Economics

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)


Dive into the research topics of 'Economic burden of asthma: Implications for outcomes and cost-effectiveness analyses'. Together they form a unique fingerprint.

Cite this